Complete Filing Data
Picard Medical, Inc. reported Stockholders Equity of $3.79 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Picard Medical, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income * | -$27.0M | -$21.1M |
| Revenue * | $4.9M | $4.4M |
| Selling General And Administrative Expense | $10.0M | $10.2M |
| Research And Development Expense | $3.0M | $3.4M |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$50.0K | -$15.0K |
| Operating Income Loss | -$13.3M | -$13.7M |
| Operating Expenses | $13.1M | $13.6M |
| Net Income Loss Available To Common Stockholders Basic | -$27.0M | -$23.7M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$27.0M | -$21.1M |
| Gross Profit | -$204.0K | -$112.0K |
| Cost Of Revenue | $5.1M | $4.5M |
| Comprehensive Income Net Of Tax | -$27.1M | -$21.1M |
| Interest Income Expense Nonoperating Net | -$5.4M | -$3.1M |
| Nonoperating Income Expense | -$13.7M | -$7.4M |
| Income Tax Expense Benefit | $35.0K | -$15.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$10.4M | -$6.7M | -$5.6M | -$6.2M | -$4.1M | -$2.0M |
| Revenue * | $1.2M | $2.1M | $881.0K | $694.0K | ||
| Selling General And Administrative Expense | $2.4M | $2.7M | $2.8M | $2.5M | ||
| Research And Development Expense | $951.0K | $743.0K | $961.0K | $940.0K | ||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$32.0K | -$15.0K | -$1.0K | $8.0K | -$5.0K | -$27.0K |
| Operating Income Loss | -$3.5M | -$3.5M | -$4.4M | -$3.8M | ||
| Operating Expenses | $3.4M | $3.4M | $3.8M | $3.4M | ||
| Net Income Loss Available To Common Stockholders Basic | -$10.4M | -$7.5M | -$6.9M | -$4.7M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$10.4M | -$6.7M | -$6.2M | -$4.1M | ||
| Gross Profit | -$130.0K | -$127.0K | -$673.0K | -$382.0K | ||
| Cost Of Revenue | $1.3M | $2.3M | $1.6M | $1.1M | ||
| Comprehensive Income Net Of Tax | -$10.5M | -$6.7M | -$6.2M | -$4.1M | ||
| Interest Income Expense Nonoperating Net | -$2.4M | -$1.4M | ||||
| Nonoperating Income Expense | -$6.9M | -$1.8M | ||||
| Income Tax Expense Benefit | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | $3.8M | -$44.0M | -$23.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $11.5M | $96.0K | $244.0K |
| Repayments Of Related Party Debt | $8.2M | $1.3M | |
| Preferred Stock Dividends Income Statement Impact | $0.00 | $2.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $11.4M | -$148.0K | |
| Retained Earnings Accumulated Deficit | -$76.8M | -$49.8M | |
| Property Plant And Equipment Net | $183.0K | $227.0K | |
| Other Accrued Liabilities Current | $1.9M | $2.1M | |
| Operating Lease Right Of Use Asset Amortization Expense | $349.0K | $318.0K | |
| Operating Lease Right Of Use Asset | $363.0K | $700.0K | |
| Operating Lease Liability Noncurrent | $34.0K | $421.0K | |
| Liabilities Current | $18.7M | $35.3M | |
| Liabilities And Stockholders Equity | $22.5M | $12.1M | |
| Liabilities | $18.8M | $35.8M | |
| Inventory Net | $7.3M | $8.1M | |
| Intangible Assets Net Excluding Goodwill | $509.0K | $596.0K | |
| Goodwill | $615.0K | $615.0K | |
| Finance Lease Right Of Use Asset | $152.0K | $177.0K | |
| Finance Lease Liability Noncurrent | $30.0K | $96.0K | |
| Derivative Liability Recognized On Issuance Of Convertible Notes | $4.4M | $2.5M | |
| Common Stock Value | $7.0K | $1.0K | |
| Cash And Cash Equivalents At Carrying Value | $7.5M | $96.0K | |
| Assets Current | $20.7M | $9.8M | |
| Assets | $22.5M | $12.1M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $228.0K | $278.0K | |
| Accounts Payable Current | $2.1M | $5.3M | |
| Inventory Write Down | $423.0K | $108.0K | |
| Finance Lease Principal Payments | $72.0K | $56.0K | |
| Temporary Equity Liquidation Preference | $0.00 | $25.4M | |
| Prepaid Expense And Other Assets Current | $1.2M | $955.0K | |
| Operating Lease Liability Current | $386.0K | $371.0K | |
| Finance Lease Liability Current | $77.0K | $63.0K | |
| Amortization Of Debt Discount Premium | $4.5M | $2.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $8.0M | -$54.5M | -$48.9M | -$35.4M | -$29.6M | -$25.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $2.8M | $6.0K | ||||
| Repayments Of Related Party Debt | ||||||
| Preferred Stock Dividends Income Statement Impact | $0.00 | $683.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | ||||||
| Retained Earnings Accumulated Deficit | -$72.6M | -$62.1M | ||||
| Property Plant And Equipment Net | $169.0K | $188.0K | ||||
| Other Accrued Liabilities Current | $1.8M | $2.2M | ||||
| Operating Lease Right Of Use Asset Amortization Expense | ||||||
| Operating Lease Right Of Use Asset | $474.0K | $550.0K | ||||
| Operating Lease Liability Noncurrent | $136.0K | $234.0K | ||||
| Liabilities Current | $5.4M | $45.6M | ||||
| Liabilities And Stockholders Equity | $13.5M | $11.7M | ||||
| Liabilities | $5.6M | $45.9M | ||||
| Inventory Net | $6.6M | $7.0M | ||||
| Intangible Assets Net Excluding Goodwill | $531.0K | $553.0K | ||||
| Goodwill | $615.0K | $615.0K | ||||
| Finance Lease Right Of Use Asset | $144.0K | $154.0K | ||||
| Finance Lease Liability Noncurrent | $44.0K | $61.0K | ||||
| Derivative Liability Recognized On Issuance Of Convertible Notes | ||||||
| Common Stock Value | $7.0K | $1.0K | ||||
| Cash And Cash Equivalents At Carrying Value | $2.8M | $410.0K | ||||
| Assets Current | $11.6M | $9.6M | ||||
| Assets | $13.5M | $11.7M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $230.0K | $262.0K | ||||
| Accounts Payable Current | $3.1M | $6.4M | ||||
| Inventory Write Down | ||||||
| Finance Lease Principal Payments | ||||||
| Temporary Equity Liquidation Preference | $0.00 | |||||
| Prepaid Expense And Other Assets Current | $1.1M | |||||
| Operating Lease Liability Current | $372.0K | |||||
| Finance Lease Liability Current | $64.0K | |||||
| Amortization Of Debt Discount Premium |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Proceeds From Related Party Debt | $3.9M | $9.4M |
| Proceeds From Issuance Of Common Stock | $15.2M | $0.00 |
| Proceeds From Convertible Debt | $2.0M | $3.7M |
| Net Cash Provided By Used In Operating Activities | -$15.7M | -$11.9M |
| Net Cash Provided By Used In Financing Activities | $27.1M | $11.7M |
| Increase Decrease In Inventories | -$390.0K | $1.3M |
| Increase Decrease In Accounts Receivable | $120.0K | -$116.0K |
| Increase Decrease In Operating Lease Liability | -$372.0K | -$311.0K |
| Share Based Compensation | $754.0K | $886.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $250.0K | $72.0K |
| Increase Decrease In Accrued Liabilities | $361.0K | $350.0K |
| Increase Decrease In Accounts Payable | -$3.2M | $2.2M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$50.0K | -$15.0K |
| Depreciation Depletion And Amortization | $163.0K | $226.0K |
| Net Cash Provided By Used In Investing Activities | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 |
|---|---|
| Proceeds From Related Party Debt | |
| Proceeds From Issuance Of Common Stock | $500.0K |
| Proceeds From Convertible Debt | |
| Net Cash Provided By Used In Operating Activities | |
| Net Cash Provided By Used In Financing Activities | |
| Increase Decrease In Inventories | |
| Increase Decrease In Accounts Receivable | |
| Increase Decrease In Operating Lease Liability | |
| Share Based Compensation | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | |
| Increase Decrease In Accrued Liabilities | |
| Increase Decrease In Accounts Payable | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | |
| Depreciation Depletion And Amortization | |
| Net Cash Provided By Used In Investing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2021 |
|---|---|---|---|
| Common Stock Shares Authorized | 150.0M | 150.0M | |
| Weighted Average Number Of Shares Outstanding Basic | 36.2M | 7.9M | |
| Earnings Per Share Basic | $-0.75 | $-2.99 | |
| Temporary Equity Shares Authorized | 30.0M | 30.0M | 30.0M |
| Common Stock Shares Outstanding | 73.7M | 7.9M | |
| Common Stock Shares Issued | 73.7M | 9.3M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |
| Temporary Equity Shares Outstanding | 0.00 | 18.4M | |
| Temporary Equity Shares Issued | 0.00 | 18.4M | |
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q3 2024 | Q1 2021 |
|---|---|---|---|---|
| Common Stock Shares Authorized | 150.0M | 45.0M | ||
| Weighted Average Number Of Shares Outstanding Basic | 54.5M | 7.9M | ||
| Earnings Per Share Basic | $-0.19 | $-0.87 | ||
| Temporary Equity Shares Authorized | 30.0M | |||
| Common Stock Shares Outstanding | 73.7M | 9.3M | ||
| Common Stock Shares Issued | 73.7M | 10.3M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | ||
| Temporary Equity Shares Outstanding | 0.00 | |||
| Temporary Equity Shares Issued | 0.00 | |||
| Temporary Equity Par Or Stated Value Per Share | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $754.0K | $886.0K |
| Gain Loss On Derivative Instruments Net Pretax | -$7.0M | -$4.3M |
| Additional Paid In Capital | $80.4M | $5.6M |
| Interest Paid Net | $259.0K | $1.0K |
| Derivative Gain Loss On Derivative Net | -$7.0M | -$4.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $204.0K | $183.0K | $141.0K | $435.0K | $194.0K | $31.0K |
| Gain Loss On Derivative Instruments Net Pretax | -$4.5M | -$380.0K | ||||
| Additional Paid In Capital | $80.3M | $7.4M | ||||
| Interest Paid Net | ||||||
| Derivative Gain Loss On Derivative Net |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.